HEALTHEQUITY, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HEALTHEQUITY, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jan 31, 2018 | $60.44M | Mar 28, 2018 |
| FY2018 | Oct 31, 2017 | $56.79M | Mar 28, 2018 |
| FY2018 | Jul 31, 2017 | $56.88M | Mar 28, 2018 |
| FY2018 | Apr 30, 2017 | $55.42M | Mar 28, 2018 |
| FY2018 | Jan 31, 2017 | $46.81M | Mar 28, 2018 |
| FY2018 | Oct 31, 2016 | $43.36M | Mar 28, 2018 |
| FY2018 | Jul 31, 2016 | $44.19M | Mar 28, 2018 |
| FY2018 | Apr 30, 2016 | $44.01M | Mar 28, 2018 |
| FY2017 | Jan 31, 2016 | $35.89M | Mar 30, 2017 |
| FY2017 | Oct 31, 2015 | $30.56M | Mar 30, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.31B | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $1.20B | Mar 17, 2026 |
| FY2024 | Jan 31, 2024 | $262.39M | Mar 22, 2024 |
| FY2024 | Oct 31, 2023 | $249.22M | Mar 22, 2024 |
| FY2024 | Jul 31, 2023 | $243.55M | Mar 22, 2024 |
| FY2024 | Apr 30, 2023 | $244.43M | Mar 22, 2024 |
| FY2024 | Jan 31, 2023 | $233.84M | Mar 22, 2024 |
| FY2024 | Oct 31, 2022 | $216.09M | Mar 22, 2024 |
| FY2024 | Jul 31, 2022 | $206.14M | Mar 22, 2024 |
| FY2024 | Apr 30, 2022 | $205.68M | Mar 22, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $215.20M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $96.70M | Mar 17, 2026 |
| FY2024 | Jan 31, 2024 | $26.36M | Mar 22, 2024 |
| FY2024 | Oct 31, 2023 | $14.67M | Mar 22, 2024 |
| FY2024 | Jul 31, 2023 | $10.58M | Mar 22, 2024 |
| FY2024 | Apr 30, 2023 | $4.09M | Mar 22, 2024 |
| FY2024 | Jan 31, 2023 | ($209.0K) | Mar 22, 2024 |
| FY2024 | Oct 31, 2022 | ($1.64M) | Mar 22, 2024 |
| FY2024 | Jul 31, 2022 | ($10.65M) | Mar 22, 2024 |
| FY2024 | Apr 30, 2022 | ($13.64M) | Mar 22, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $322.46M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $162.33M | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | $117.70M | Mar 17, 2026 |
| FY2025 | Jan 31, 2023 | $9.06M | Mar 18, 2025 |
| FY2024 | Jan 31, 2022 | ($24.24M) | Mar 22, 2024 |
| FY2023 | Jan 31, 2021 | $34.01M | Mar 30, 2023 |
| FY2022 | Jan 31, 2020 | $77.01M | Mar 31, 2022 |
| FY2021 | Jan 31, 2019 | $77.67M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $54.42M | Mar 31, 2020 |
| FY2019 | Jan 31, 2017 | $41.21M | Mar 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $3.38B | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $3.45B | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | $3.16B | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | $3.09B | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | $3.11B | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | $2.71B | Mar 31, 2022 |
| FY2021 | Jan 31, 2020 | $2.56B | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $510.02M | Mar 31, 2020 |
| FY2019 | Jan 31, 2018 | $369.16M | Mar 28, 2019 |
| FY2018 | Jan 31, 2017 | $279.14M | Mar 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.27B | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $1.33B | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | $1.13B | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | $1.19B | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | $1.25B | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | $1.33B | Mar 31, 2022 |
| FY2021 | Jan 31, 2020 | $1.53B | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $32.94M | Mar 31, 2020 |
| FY2019 | Jan 31, 2018 | $22.89M | Mar 28, 2019 |
| FY2018 | Jan 31, 2017 | $17.20M | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $2.11B | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $2.11B | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | $2.04B | Mar 17, 2026 |
| FY2026 | Jan 31, 2023 | $1.90B | Mar 17, 2026 |
| FY2025 | Jan 31, 2022 | $1.85B | Mar 18, 2025 |
| FY2024 | Jan 31, 2021 | $1.38B | Mar 22, 2024 |
| FY2023 | Jan 31, 2020 | $1.03B | Mar 30, 2023 |
| FY2022 | Jan 31, 2019 | $477.08M | Mar 31, 2022 |
| FY2021 | Jan 31, 2018 | $346.27M | Mar 31, 2021 |
| FY2020 | Jan 31, 2017 | $261.94M | Mar 31, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 2 | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | 1 | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | 0 | Mar 17, 2026 |
| FY2025 | Jan 31, 2023 | 0 | Mar 18, 2025 |
| FY2024 | Jan 31, 2022 | 0 | Mar 22, 2024 |
| FY2023 | Jan 31, 2021 | 0 | Mar 30, 2023 |
| FY2020 | Jan 31, 2020 | 0 | Mar 31, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Mar 31, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Mar 31, 2020 |
| FY2020 | Apr 30, 2019 | 0 | Mar 31, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 2 | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | 1 | Mar 17, 2026 |
| FY2026 | Jan 31, 2024 | 0 | Mar 17, 2026 |
| FY2025 | Jan 31, 2023 | 0 | Mar 18, 2025 |
| FY2024 | Jan 31, 2022 | 0 | Mar 22, 2024 |
| FY2023 | Jan 31, 2021 | 0 | Mar 30, 2023 |
| FY2020 | Jan 31, 2020 | 0 | Mar 31, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Mar 31, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Mar 31, 2020 |
| FY2020 | Apr 30, 2019 | 0 | Mar 31, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $318.93M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $295.95M | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | $403.98M | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | $254.27M | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | $225.41M | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | $328.80M | Mar 31, 2022 |
| FY2021 | Jan 31, 2020 | $191.73M | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $361.48M | Mar 31, 2020 |
| FY2019 | Jan 31, 2018 | $199.47M | Mar 28, 2019 |
| FY2019 | Jan 31, 2017 | $139.95M | Mar 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $957.38M | Mar 17, 2026 |
| FY2026 | Jan 31, 2025 | $1.06B | Mar 17, 2026 |
| FY2025 | Jan 31, 2024 | $874.97M | Mar 18, 2025 |
| FY2024 | Jan 31, 2023 | $925.34M | Mar 22, 2024 |
| FY2023 | Jan 31, 2022 | $930.83M | Mar 30, 2023 |
| FY2022 | Jan 31, 2021 | $986.72M | Mar 31, 2022 |
| FY2020 | Jan 31, 2020 | $1.22B | Mar 31, 2020 |